Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov 25;8(1):11-24.
doi: 10.1093/gastro/goz061. eCollection 2020 Feb.

Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?

Nicolas Huyghe  1 , Paméla Baldin  2 , Marc Van den Eynde  1   3
Affiliations
Review

Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?

Nicolas Huyghe et al. Gastroenterol Rep (Oxf). .

Abstract

Following initial success in melanoma and lung tumours, immune checkpoint inhibitors (ICIs) are now well recognized as a major immunotherapy treatment modality for multiple types of solid cancers. In colorectal cancer (CRC), the small subset that is mismatch-repair-deficient and microsatellite-instability-high (dMMR/MSI-H) derive benefit from immunotherapy; however, the vast majority of patients with proficient MMR (pMMR) or with microsatellite stable (MSS) CRC do not. Immunoscore and the consensus molecular subtype classifications are promising biomarkers in predicting therapeutic efficacy in selected CRC. In pMRR/MSS CRC, biomarkers are also needed to understand the molecular mechanisms governing immune reactivity and to predict their relationship to treatment. The continuous development of such biomarkers would offer new perspectives and more personalized treatments by targeting oncological options, including ICIs, which modify the tumour-immune microenvironment. In this review, we focus on CRC and discuss the current status of ICIs, the role of biomarkers to predict response to immunotherapy, and the approaches being explored to render pMMR/MSS CRC more immunogenic through the use of combined therapies.

Keywords: colorectal cancer; immune checkpoint inhibitors; immune response; immunoscore; immunotherapy.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Schematic representation of colorectal-cancer-immune subgroups, linked biomarkers, and potential treatment strategies. ‘Immunocompetent’ tumour (green circle) is characterized by a coordinated immune response with high T-cells (CD3, CD8, and Th1), macrophage infiltration, and upregulation of immune checkpoint molecules (CTLA-4, PD-1, and PD-L1). ‘Immune evasion’ group (blue circle) is characterized by poor immune cell infiltration. ‘Immunosuppressed’ group (red circle) is characterized by high immune cell infiltration as well as a high infiltration of suppressor cells with suppressive cytokine release. The ‘immune evasion’ and the ‘immunosuppressed’ groups could be treated with radiotherapy, chemotherapy, targeted therapy, cytokine modulation, or other approaches such as COX inhibition or A2AR inhibition, to render the tumours more immunogenic so that they benefit from ICIs. Possible biomarkers of response to ICIs are marked from 1 to 6. (1) PD-1/PD-L1 expression. (2) Tumour-mutation burden. (3) Mutation-associated neoantigens presentation on HLA class I. (4) High cytotoxic immune cells infiltration (immunoscore). (5) Gene-expression signature (including CMS classification). (6) Gut microbiome. A2AR, adenosine A2A receptor; COX, cyclooxygenase-2; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; HLA, human leucocyte antigens; IFN-γ, interferon-gamma; IL-17, interleukin 17; MDSC, myeloid-derived suppressor-derived cells; PD-1, programmed death protein 1; PD-L1, programmed death-ligand 1; TCR, T-cell receptor; TGF-β, transforming growth factor-beta; Th17, T helper 17; CMS, consensus molecular subtype.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ferlay J, Colombet M, Soerjomataram I. et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019;144:1941–53. - PubMed
    1. Arnold M, Sierra MS, Laversanne M. et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut 2017;66:683–91. - PubMed
    1. Khalil DN, Smith EL, Brentjens RJ. et al. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol 2016;13:273–90. - PMC - PubMed
    1. Schreiber RD, Old LJ, Smyth MJ.. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011;331:1565–70. - PubMed
    1. Sharma P, Allison JP.. The future of immune checkpoint therapy. Science 2015;348:56–61. - PubMed